Peptide Laws by State: US Legality Guide (2026)

Peptide legality in the United States is set mainly at the federal level, not state by state. No state independently schedules research peptides as a separate drug class. Instead, each state layers prescription-drug rules, medical-practice acts, and telehealth requirements on top of the FDA's federal framework, which is shifting fast in 2026.

Peptide laws by US state at a glance

• Governing layer: primarily federal (FDA, FD&C Act), then state prescription and medical-practice rules
• DEA scheduling: most research peptides are not DEA-scheduled controlled substances
• HGH (somatropin/somatrem): federally restricted — non-medical distribution is a felony (21 U.S.C. §333(e))
• Compounding status: governed by 503A / 503B and the FDA "bulks list" categories, not by individual states
• Key 2026 event: PCAC meeting July 23–24, 2026 reviewing 7 peptides (BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, Epitalon)
• What varies by state: telehealth prescribing rules, pharmacy licensing, and enforcement posture — not a separate "peptide schedule"

Are peptide laws actually different in each US state?

For research peptides, mostly no. The common belief that peptides are "legal in some states and banned in others" — the way cannabis is — does not match how the law works. The substances that drive most peptide questions (BPC-157, TB-500, semaglutide analogs, growth-hormone-releasing peptides) are regulated as drugs under the federal Food, Drug, and Cosmetic Act, administered by the FDA. That federal status applies in all 50 states.

No individual state has created a distinct controlled-substance schedule that singles out research peptides as a unique class. States can add restrictions on top of federal law — for example, stricter telehealth-prescribing rules or pharmacy-licensing requirements — but a state cannot make a federally unapproved drug broadly legal for human use, and most have not tried to carve out special peptide categories [VERIFY: confirm no state has enacted a peptide-specific controlled-substance statute as of June 2026].

So the practical question is rarely "is this peptide legal in my state?" It is usually "under what federal pathway can I legally obtain this peptide, and does my state's prescribing or pharmacy law add a barrier?"

Legal status varies by jurisdiction; consult a lawyer for binding advice.

What does federal law say about peptide legality?

Federal law is the controlling layer, and it sorts peptides into a few buckets.

FDA-approved peptide drugs. Some peptides are approved drugs with a brand name and an FDA label — for example, semaglutide and tirzepatide. These are legal nationwide with a valid prescription, dispensed by a licensed pharmacy. State medical-practice acts govern who may prescribe and how.

Compounded peptides (the 503A/503B system). A licensed pharmacy may compound certain drugs for an individual patient under section 503A, or as an outsourcing facility under 503B. Whether a bulk peptide may be compounded depends on the FDA's "503A bulks list," which sorts nominated substances into categories. Category 1 substances may be used under the FDA's interim enforcement-discretion policy; Category 2 substances "raise significant safety concerns" and are not eligible for that policy (FDA, Bulk Drug Substances Used in Compounding Under Section 503A; Certain Bulk Drug Substances That May Present Significant Safety Risks).

"Research use only" (RUO) peptides. Many vials are sold labeled "for research use only / not for human consumption." Selling a peptide to a genuine laboratory for research is generally lawful. But the FDA's position is that intended use — not the label — controls: a vial marketed with human dosing instructions is treated as an unapproved new drug, regardless of the RUO sticker.

HGH is a special federal case. Human growth hormone (somatrem, somatropin, or an analogue) is not a classic DEA-scheduled drug, but federal statute makes it a felony to "knowingly distribute, or possess with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition" authorized by FDA and ordered by a physician — punishable by up to 5 years in prison (21 U.S.C. §333(e)). The FDA interprets "distribution" to include writing a prescription. This restriction is uniform across all states.

This section is regulatory, not medical. Consult your healthcare provider before considering any peptide, and a lawyer for jurisdiction-specific legal questions.

Why is BPC-157 the center of the 2026 legality debate?

BPC-157 is the clearest example of why "peptide legality" is complicated. It has real preclinical research behind it but no human approval and no clean legal pathway.

On the science side, BPC-157 has been studied in animal models for connective-tissue repair. In a rat study, the pentadecapeptide BPC 157 promoted tendon-fibroblast outgrowth, cell survival under oxidative stress, and cell migration (Chang et al., 2011, Journal of Applied Physiology, PMID 21030672). A follow-up in-vitro study reported that BPC 157 upregulated growth-hormone-receptor expression in tendon fibroblasts, a proposed mechanism for its healing effects (Chang et al., 2014, Molecules, PMID 25415472). Research in animal and cell models suggests BPC-157 may support tendon healing; human clinical evidence is limited.

On the legal side, BPC-157 is not FDA-approved for human use. It does not meet the DSHEA definition of a dietary ingredient, so it cannot lawfully be marketed as a dietary supplement; the Department of Defense's Operation Supplement Safety program states plainly that "BPC-157 is not a dietary ingredient" and that it is "an unapproved drug" (OPSS, U.S. DoD). It is also prohibited in sport — the World Anti-Doping Agency lists BPC-157 under category S0 (non-approved substances) (USADA). Critically, BPC-157 had been placed in Category 2 of the 503A bulks list, meaning compounding pharmacies had no enforcement-discretion pathway to use it.

For a deeper breakdown, see our BPC-157 complete guide and the BPC-157 legal status explainer.

Consult your healthcare provider before starting any peptide protocol.

What is the FDA's July 2026 PCAC meeting, and why does it matter?

The single most important 2026 development is a scheduled vote that could change the compounding status of seven peptides nationwide.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting July 23–24, 2026 at the FDA's White Oak campus in Silver Spring, Maryland (FDA, 2026 Meeting Materials, PCAC; July 23–24, 2026 Meeting calendar notice). The committee will discuss whether seven peptides should move toward the 503A bulks list:

• July 23: BPC-157, KPV, TB-500 (a thymosin beta-4 fragment), and MOTS-c
• July 24: Emideltide (delta sleep-inducing peptide, DSIP), Semax, and Epitalon

Comments are filed under Docket No. FDA-2026-N-2979. In the lead-up, FDA also took procedural steps in April 2026 to remove a set of peptides from Category 2. According to legal analysis from Hyman, Phelps & McNamara's FDA Law Blog, that removal does not by itself authorize compounding — removal from Category 2 is not the same as Category 1 eligibility, and a substance must still clear the process to gain enforcement discretion (FDA Law Blog, "FDA's Pep(tide) Rally," April 2026).

Two points matter for anyone reading legality headlines:

1. A PCAC vote is a recommendation, not a law. Even if PCAC recommends adding a peptide to Category 1 and FDA agrees, notice-and-comment rulemaking is still required — a process that can take more than a year.
2. "Coming off the do-not-compound list" ≠ "legal to buy over the counter." These peptides would remain prescription-only and would still require a licensed prescriber and a licensed compounding pharmacy.

This is a regulatory snapshot as of June 5, 2026, and is subject to change. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Which peptides are most restricted, and which have the clearest legal path?

It helps to group peptides by how the law treats them, rather than by state.

Clearest legal path — FDA-approved peptides. Semaglutide, tirzepatide, and other approved peptide drugs are legal nationwide with a valid prescription from a licensed provider. The state-level variable is the prescribing relationship (in-person vs. telehealth) and your state's medical-practice and pharmacy rules.

Conditional path — compounded peptides. Peptides a pharmacy may lawfully compound depend on FDA bulks-list status. Some peptides used in legitimate compounding (for example, certain GnRH-type agents prescribed and compounded under medical oversight) sit in this conditional zone [VERIFY: confirm current compounding status of any specific peptide before relying on it].

Highest-restriction — unapproved / Category-2-history peptides. BPC-157, TB-500, Semax, Epitalon, MOTS-c, KPV, and DSIP/Emideltide are the peptides under the July 2026 PCAC review precisely because they lacked a clean pathway. Until rulemaking concludes, treating them as freely legal for human use is not accurate.

Special federal restriction — HGH. As noted, HGH distribution outside an approved medical indication is a federal felony in every state (21 U.S.C. §333(e)).

Consult your healthcare provider before starting any peptide protocol, and a licensed attorney for legal questions specific to your state.

How do I check peptide legality for my own situation?

Because the rules are federal-first, a practical checklist beats a 50-state table:

1. Is the peptide FDA-approved? If yes (e.g., semaglutide), it is legal nationwide with a prescription.
2. Is it on the 503A bulks list, and in which category? Category 1 has an enforcement-discretion pathway; Category 2 does not.
3. Is it one of the seven PCAC peptides? If so, its status may change after July 2026 — but not instantly.
4. Does your state add telehealth or pharmacy restrictions? Some states (New York among them) have tightened telehealth-prescribing documentation rules [VERIFY: current NY telehealth-prescribing requirements as of 2026].
5. Is it HGH or an analogue? If so, the strict federal §333(e) rule applies everywhere.

If you are trying to find a legitimate, licensed provider rather than a gray-market vendor, see our NYC peptide doctors directory and our explainer on 503A vs. 503B compounding.

Consult your healthcare provider before starting any peptide protocol. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Frequently asked questions

Q: Are peptides legal in all 50 states? A: Peptide legality is set primarily by federal law, so the answer is roughly the same across all 50 states. FDA-approved peptides (like semaglutide) are legal nationwide with a prescription. Unapproved research peptides such as BPC-157 lack a clean legal pathway for human use everywhere. No state separately schedules research peptides as a unique drug class, though states can add telehealth and pharmacy rules. This is educational information, not legal advice — consult a licensed attorney for your situation.

Q: Is BPC-157 legal in 2026? A: As of June 2026, BPC-157 is not FDA-approved, is not a lawful dietary supplement under DSHEA, and is prohibited in sport under WADA category S0. It had been placed in Category 2 of the FDA 503A bulks list, meaning no compounding enforcement-discretion pathway. It is one of seven peptides under PCAC review on July 23, 2026. Its status may evolve, but it is not currently a freely legal consumer product. Consult your healthcare provider and a lawyer.

Q: What is the FDA PCAC meeting in July 2026? A: The Pharmacy Compounding Advisory Committee meets July 23–24, 2026 at FDA's White Oak campus to discuss whether seven peptides — BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon — should move toward the 503A bulks list. Comments are filed under Docket FDA-2026-N-2979. A PCAC recommendation is advisory only; formal rulemaking, which can take over a year, would still be required before any change takes effect.

Q: Does any state ban peptides specifically? A: No state has enacted a controlled-substance schedule that singles out research peptides as their own class, based on available information. States regulate peptides indirectly — through prescription-drug requirements, medical-practice acts, and telehealth-prescribing rules — layered on top of federal FDA law. A state cannot make a federally unapproved drug broadly legal for human use. Always verify current state pharmacy and telehealth rules with a licensed attorney before acting [VERIFY: state-specific statutes].

Q: Can I get peptides legally through telehealth? A: For non-controlled peptides, telehealth prescribing is governed by state medical-practice acts rather than DEA rules. Most states permit telehealth prescriptions of non-controlled drugs once a valid provider-patient relationship is established, but documentation requirements vary, and some states impose stricter rules. The peptide itself must still have a lawful pathway (FDA-approved or properly compounded). Consult your healthcare provider, and verify your state's specific telehealth requirements.

Q: Is HGH treated differently from other peptides? A: Yes. Human growth hormone (somatrem, somatropin, or an analogue) is governed by a specific federal statute, 21 U.S.C. §333(e), which makes non-medical distribution a felony punishable by up to 5 years in prison. The FDA interprets "distribution" to include writing a prescription outside an approved indication. This rule applies uniformly in every state and is stricter than the framework for most research peptides.

Q: Will the July 2026 PCAC vote make peptides legal to buy over the counter? A: No. Even a favorable PCAC vote followed by FDA rulemaking would, at most, allow these peptides to be compounded by licensed pharmacies under a valid prescription. They would remain prescription-only drugs, not over-the-counter products, and the rulemaking process can take more than a year. Treat any "peptides are legal again" headline as shorthand for a narrow compounding change, not open retail access.

References

1. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
3. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
4. U.S. Food and Drug Administration. 2026 Meeting Materials, Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/2026-meeting-materials-pharmacy-compounding-advisory-committee
5. Hyman, Phelps & McNamara, P.C. FDA's Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2), FDA Law Blog, April 2026. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
6. 21 U.S. Code §333(e) — Penalties (human growth hormone). Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/333
7. Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. PMID 21030672. https://pubmed.ncbi.nlm.nih.gov/21030672/
8. Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMID 25415472. https://pubmed.ncbi.nlm.nih.gov/25415472/
9. U.S. Department of Defense, Operation Supplement Safety (OPSS). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
10. U.S. Anti-Doping Agency (USADA). BPC-157: Experimental Peptide Creates Risk for Athletes. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/